[1] DENG Y, LI H, WANG M, et al. Global burden of thyroid cancer from 1990 to 2017[J]. JAMA Netw Open, 2020, 3(6): e208759.
[2] HUGHES D T, HAYMART M R, MILLER B S, et al. The most commonly occurring papillary thyroid cancer in the United States is now a microcarcinoma in a patient older than 45 years[J]. Thyroid, 2011, 21(3): 231-236.
[3] WANG J, YU F, SHANG Y, et al. Thyroid cancer: incidence and mortality trends in China, 2005-2015[J]. Endocrine, 2020, 68(1): 163-173.
[4] GIRARDI F M. Thyroid carcinoma pattern presentation according to age[J]. Int Arch Otorhinolaryngol, 2017, 21(1): 38-41.
[5] PARK H S, ROMAN S A, SOSA J A. Treatment patterns of aging Americans with differentiated thyroid cancer[J]. Cancer, 2010, 116(1):20-30.
[6] SHI L Y, LIU J, YU L J, et al. Clinic-pathologic features and prognostic analysis of thyroid cancer in the older adult: a SEER based study[J]. J Cancer, 2018, 9(15): 2744-2750.
[7] 刘晓云, 徐书杭, 邬宏恂, 等. 加强甲状腺结节细针穿刺规范化管理[J]. 中华内分泌代谢杂志, 2019, 35(10): 819-824.
[8] LI X J, MAO X D, CHEN G F, et al. High BRAFV600E mutation frequency in Chinese patients with papillary thyroid carcinoma increases diagnostic efficacy in cytologically indeterminate thyroid nodules[J]. Medicine: Baltimore, 2019, 98(28): e16343.
[9] ITO Y, MIYAUCHI A, KIHARA M, et al. Patient age is significantly related to the progression of papillary microcarcinoma of the thyroid under observation[J]. Thyroid, 2014, 24(1): 27-34.
[10] KOSHKINA A, FAZELZAD R, SUGITANI I, et al. Association of patient age with progression of low-risk papillary thyroid carcinoma under active surveillance: a systematic review and meta-analysis[J]. JAMA Otolaryngol Head Neck Surg, 2020, 146(6): 552-560.
[11] TUTTLE R M, FAGIN J A, MINKOWITZ G, et al. Natural history and tumor volume kinetics of papillary thyroid cancers during active surveillance[J]. JAMA Otolaryngol Head Neck Surg, 2017, 143(10): 1015-1020.
[12] BRITO J P, ITO Y, MIYAUCHI A, et al. A clinical framework to facilitate risk stratification when considering an active surveillance alternative to immediate biopsy and surgery in papillary microcarcinoma[J]. Thyroid, 2016, 26(1): 144-149.
[13] 高明, 葛明华, 嵇庆海, 等. 甲状腺微小乳头状癌诊断与治疗中国专家共识(2016版)[J]. 中国肿瘤临床, 2016, 43(10): 405-411.
[14] XU D, GE M, YANG A, et al. Expert consensus workshop report: Guidelines for thermal ablation of thyroid tumors (2019 edition)[J]. J Cancer Res Ther, 2020, 16(5): 960-966.
[15] CHOI Y, JUNG S L. Efficacy and safety of thermal ablation techniques for the treatment of primary papillary thyroid microcarcinoma: a systematic review and meta-analysis[J]. Thyroid, 2020, 30(5): 720-731.
[16] LI J, LIU Y, LIU J, et al. Ultrasound-guided percutaneous microwave ablation versus surgery for papillary thyroid microcarcinoma[J]. Int J Hyperthermia, 2018, 34(5): 653-659.
[17] LI J, LIU Y, LIU J, et al. A comparative study of short-term efficacy and safety for thyroid micropapillary carcinoma patients after microwave ablation or surgery[J]. Int J Hyperthermia, 2019, 36(1): 640-646.
[18] ZHANG M, TUFANO R P, RUSSELL J O, et al. Ultrasound-guided radiofrequency ablation versus surgery for low-risk papillary thyroid microcarcinoma: Results of over 5 years’ follow-up[J]. Thyroid, 2020, 30(3): 408-417.
[19] TONG M, LI S, LI Y, et al. Efficacy and safety of radiofrequency, microwave and laser ablation for treating papillary thyroid microcarcinoma: a systematic review and meta-analysis[J]. Int J Hyperthermia, 2019, 36(1): 1278-1286.
[20] JOSEPH K R, EDIRIMANNE S, ESLICK G D. Thyroidectomy for thyroid cancer in the elderly: a meta-analysis[J]. Eur J Surg Oncol, 2019, 45(3): 310-317.
[21] ZAMBELI-LJEPOVIĆ A, WANG F, DINAN M A, et al. Low-risk thyroid cancer in elderly: total thyroidectomy/RAI predominates but lacks survival advantage[J]. J Surg Res, 2019, 243: 189-197.
[22] 中国抗癌协会甲状腺癌专业委员会. 甲状腺癌血清标志物临床应用专家共识(2017版)[J]. 中国肿瘤临床, 2018, 45(1): 7-13.
[23] HAUGEN B R, ALEXANDER E K, BIBLE K C, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer[J]. Thyroid, 2016, 26(1): 1-133.
[24] LEE M C, KIM M J, CHOI H S, et al. Postoperative thyroid-stimulating hormone levels did not affect recurrence after thyroid lobectomy in patients with papillary thyroid cancer[J]. Endocrinol Metab: Seoul, 2019, 34(2): 150-157.
[25] PARK S, KIM W G, HAN M, et al. Thyrotropin suppressive therapy for low-risk small thyroid cancer: a propensity score-matched cohort study[J]. Thyroid, 2017, 27(9): 1164-1170.
[26] CARRANZA F H, IGLESIAS S G, DE MINGO DOMÍNGUEZ M L, et al. Trabecular bone deterioration in differentiated thyroid cancer: impact of long-term TSH suppressive therapy[J]. Cancer Med, 2020, 9(16): 5746-5755.
[27] MAZZIOTTI G, FORMENTI A M, FRARA S, et al. High prevalence of radiological vertebral fractures in women on thyroid-stimulating hormone-suppressive therapy for thyroid carcinoma[J]. J Clin Endocrinol Metab, 2018, 103(3): 956-964.
[28] TAM S, BOONSRIPITAYANON M, AMIT M, et al. Survival in differentiated thyroid cancer: comparing the AJCC cancer staging seventh and eighth editions[J]. Thyroid, 2018, 28(10): 1301-1310.
[29] WANG X, LEI J, WEI T, et al. Clinicopathological characteristics and recurrence risk of papillary thyroid microcarcinoma in the elderly[J]. Cancer Manag Res, 2019, 11: 2371-2377.
[30] HAN J M, BAE J C, KIM H I, et al. Clinical outcomes of differentiated thyroid cancer patients with local recurrence or distant metastasis detected in old age[J]. Endocrinol Metab Seoul: 2018, 33(4): 459-465. |
